$331.170
+1.258 (+0.38%)收盤時
LH 資訊
LH 事件
Vertiv Holdings Gains $28.67 to $237.23
Notable gainers among liquid option names this morning include Vertiv Holdings (VRT) $237.23 +28.67, LabCorp (LH) $359.35 +28.18, Fortive (FTV) $66.75 +5.13, GE Hlthcare Tech Inc (GEHC) $76.32 +5.21, and Flex (FLEX) $87.75 +4.40.
Labcorp Raises FY26 Revenue Outlook to $14.78B
Consensus $18.35. Raises FY26 revenue view to $14.78B-$14.89B from $14.71B-$14.83B, consensus $14.75B. Backs FY26 free cash flow view $1.24B-$1.36B. The company said, "Labcorp is updating 2026 full year guidance to reflect its third quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of September 30, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends."
Labcorp Reports Q3 Revenue of $3.81B, Exceeding Expectations
Reports Q3 revenue $3.81B, consensus $3.76B. "Labcorp delivered another strong quarter with 7% revenue growth, continued margin expansion and 14.5% adjusted EPS growth, leading to a raise in our full-year guidance," said Adam Schechter, Chairman and CEO of Labcorp. "We furthered our leadership in specialty testing by launching innovative tests for advanced melanoma, Alzheimer's disease, and hepatitis D, while expanding access through strategic acquisitions across our Diagnostics and Biopharma Laboratory Services businesses. As healthcare continues to be transformed by advances in science and technology, personalized medicine, and evolving consumer expectations, Labcorp is well positioned to capitalize on these trends and drive sustainable long-term growth."
Labcorp Partners with Waters to Expand HPV Testing Services
Labcorp (LH) and Waters (WAT) announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026. Cervical cancer is largely preventable through routine screening and early detection of human papillomavirus, yet millions of women remain overdue for recommended tests. This collaboration is designed to help address persistent cervical cancer screening gaps by bringing more accessible screening options to patients across the United States. Labcorp will provide these HPV testing options to support its clinician programs, Gaps in Care health plan programs, and Labcorp OnDemand consumer channel.
Labcorp Collaborates with FDA and Charles River to Advance Drug Abuse Potential Evaluation
Labcorp (LH) announced a collaboration with the FDA and Charles River Laboratories (CRL) to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused. The research aims to support safer drug development and more informed regulatory decisions. The collaboration brings together complementary expertise from industry and government. Labcorp will contribute its experience conducting regulatory abuse potential studies, while FDA scientists will conduct data analysis and contribute regulatory science expertise. Together, the organizations aim to advance the science used to evaluate the risk that a medicine could be abused using harmonized behavioral economics methodology to quantify and rank abuse potential.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。